Half-year report · HY
2158.TEDINET S100X4KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥6m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥290m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥23m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥544m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥20m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥555m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥102m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥753m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥369m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥254m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥123m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥689m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥913m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥564m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.86 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.25 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥5.24 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 39.1% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| DXreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥61m |
| Life Science AIreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥216m |
| Risk Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥150m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | −¥6m |
| DXreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥34m |
| Life Science AIreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥122m |
| Risk Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥290m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 564
| Item | Context | Value | Unit |
|---|---|---|---|
| Gain on reversal of subscription rights to shares ope cf | InterimDuration | -55388000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1InterimDuration | 1510000 | JPY |
| Increase decrease in net defined benefit liability ope cf | InterimDuration | 4289000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1InterimDuration | -16458000 | JPY |
| Increase decrease in provision for bonuses ope cf | InterimDuration | -40878000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1InterimDuration | -1536000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | InterimDuration | 99000 | JPY |
| Increase decrease in provision for loss on order received ope cf | Prior1InterimDuration | － | JPY |
| Increase decrease in provision for loss on order received ope cf | InterimDuration | 4680000 | JPY |
| Interest and dividends income ope cf | Prior1InterimDuration | -30039000 | JPY |
| Interest and dividends income ope cf | InterimDuration | -35533000 | JPY |
| Interest expenses ope cf | Prior1InterimDuration | 12856000 | JPY |
| Interest expenses ope cf | InterimDuration | 20685000 | JPY |
| Foreign exchange losses gains ope cf | Prior1InterimDuration | -27423000 | JPY |
| Foreign exchange losses gains ope cf | InterimDuration | -90000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | 478048000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | 204999000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -5062000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -26103000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1InterimDuration | -9146000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | InterimDuration | 67903000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1InterimDuration | -214542000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | InterimDuration | -14097000 | JPY |
| Other net ope cf | Prior1InterimDuration | -217321000 | JPY |
| Other net ope cf | InterimDuration | -165319000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | 446131000 | JPY |
| Subtotal ope cf | InterimDuration | 201996000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 30039000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 35533000 | JPY |
| Proceeds from insurance income ope cf | Prior1InterimDuration | 15278000 | JPY |
| Proceeds from insurance income ope cf | InterimDuration | － | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -13045000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -22345000 | JPY |
| Settlement package paid ope cf | Prior1InterimDuration | -76390000 | JPY |
| Settlement package paid ope cf | InterimDuration | － | JPY |
| Expenses related to suspended businesses ope cf | Prior1InterimDuration | － | JPY |
| Expenses related to suspended businesses ope cf | InterimDuration | -69268000 | JPY |
| Expenses related to the restructuring of overseas subsidiaries ope cf | Prior1InterimDuration | － | JPY |
| Expenses related to the restructuring of overseas subsidiaries ope cf | InterimDuration | -206600000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -33307000 | JPY |
| Income taxes paid ope cf | InterimDuration | -41407000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 368704000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | -102090000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -41078000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -19207000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from sales of property plant and equipment inv cf | InterimDuration | 9901000 | JPY |
| Purchase of intangible assets inv cf | Prior1InterimDuration | -108880000 | JPY |
| Purchase of intangible assets inv cf | InterimDuration | -170510000 | JPY |
| Purchase of investment securities inv cf | Prior1InterimDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |